Shore Capital Reiterates Sell Rating for AstraZeneca plc (AZN)
A number of other equities analysts also recently issued reports on AZN. Deutsche Bank AG restated a buy rating and issued a GBX 5,500 ($67.93) price target on shares of AstraZeneca plc in a research note on Wednesday, March 15th. HSBC Holdings plc dropped their price target on AstraZeneca plc from GBX 4,700 ($58.05) to GBX 4,500 ($55.58) and set a hold rating on the stock in a research note on Tuesday, February 7th. Barclays PLC began coverage on AstraZeneca plc in a research note on Wednesday, March 8th. They issued an overweight rating and a GBX 6,000 ($74.10) price target on the stock. Berenberg Bank dropped their price target on AstraZeneca plc from GBX 5,500 ($67.93) to GBX 5,450 ($67.31) and set a buy rating on the stock in a research note on Tuesday, February 21st. Finally, Kepler Capital Markets set a GBX 5,000 ($61.75) price target on AstraZeneca plc and gave the stock a buy rating in a research note on Thursday, December 29th. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of GBX 5,018.36 ($61.98).
AstraZeneca plc (LON:AZN) opened at 4871.50 on Wednesday. The stock has a 50 day moving average of GBX 4,617.49 and a 200-day moving average of GBX 4,602.58. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00. The firm’s market cap is GBX 61.64 billion.
Your IP Address:
The business also recently declared a dividend, which was paid on Monday, March 20th. Stockholders of record on Thursday, February 16th were paid a dividend of GBX 150.20 ($1.86) per share. This represents a dividend yield of 3.52%. The ex-dividend date of this dividend was Thursday, February 16th. This is an increase from AstraZeneca plc’s previous dividend of $68.70.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.